TrialPhase 2 Dose-finding IMU-838 for Ulcerative Colitis
Trial details
- Registry ID
- NCT03341962
- Phase
- Phase 2
IMUX
Immunic AG
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceMRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
Trial details
- Registry ID
- NCT03846219
- Phase
- Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Trial details
- Registry ID
- NCT04379271
- Phase
- Phase 2, Phase 3
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Trial details
- Registry ID
- NCT05054140
- Phase
- Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Trial details
- Registry ID
- NCT05134441
- Phase
- Phase 3
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Trial details
- Registry ID
- NCT05201638
- Phase
- Phase 3
Latest recorded trial changes
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05201638 · Immunic AG
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
1050 participants (planned)
+ After
1100 participants (actual)
Primary completion date changed
− Before
Oct 2024
+ After
Nov 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05134441 · Immunic AG
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
1050 participants (planned)
+ After
1121 participants (actual)
Primary completion date changed
− Before
Sep 2024
+ After
Nov 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting